Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1O4MP
|
|||
| Drug Name |
LY3361237
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0; ICD-9: 710.2] | Phase 2 | [1] | |
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [2] | ||
| Company |
Gilead; Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B- and T-lymphocyte attenuator (BTLA) | Target Info | Agonist | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05781451) A Phase 2, Open Label Study of Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05123586) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.